← Back to Search

Corticosteroid

Repository Corticotropin Injection -Treatment Extension for Panuveitis

N/A
Waitlist Available
Led By Daniel A Culver, DO
Research Sponsored by The Cleveland Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up measured at 24 weeks
Awards & highlights

Study Summary

Ocular Sarcoidosis Open Label Trial of ACTHAR Gel

Eligible Conditions
  • Panuveitis
  • Ocular Sarcoidosis
  • Uveitis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~measured at 24 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and measured at 24 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percentage of Patients With Clinically Significant Improvement in Visual Acuity
Secondary outcome measures
Percentage of Patients With Clinically Significant Improvement in the Resolution-intraocular Inflammation
Proportion of Patients Experiencing a Tapering of Ocular/Oral Steroids by at Least 50%
Proportion of Patients With a Clinically Significant Reduction-cystoid Macular Edema

Trial Design

1Treatment groups
Experimental Treatment
Group I: H.P. Achtar Gel 80 UExperimental Treatment2 Interventions
H.P. Acthar Gel (repository corticotropin) Injection, 80 U daily for 10 days, then 80 U twice weekly for up to a total of 24 weeks on therapy.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Repository Corticotropin Injection
2016
Completed Phase 4
~110
Repository Corticotropin Injection -Treatment Extension
2016
N/A
~10

Find a Location

Who is running the clinical trial?

The Cleveland ClinicLead Sponsor
1,026 Previous Clinical Trials
1,366,067 Total Patients Enrolled
MallinckrodtIndustry Sponsor
201 Previous Clinical Trials
16,219 Total Patients Enrolled
1 Trials studying Panuveitis
5 Patients Enrolled for Panuveitis
Daniel A Culver, DOPrincipal InvestigatorThe Cleveland Clinic

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Ocular Sarcoidosis Open Label Trial of ACTHAR Gel
2016. "Ocular Sarcoidosis Open Label Trial of ACTHAR Gel". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02725177.
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top